Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden

This case-control study examines the risk of severe COVID-19 infection in individuals with multiple sclerosis who were receiving rituximab.

Detalles Bibliográficos
Autores principales: McKay, Kyla A., Piehl, Fredrik, Englund, Simon, He, Anna, Langer-Gould, Annette, Hillert, Jan, Frisell, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637249/
https://www.ncbi.nlm.nih.gov/pubmed/34851401
http://dx.doi.org/10.1001/jamanetworkopen.2021.36697
_version_ 1784608702554177536
author McKay, Kyla A.
Piehl, Fredrik
Englund, Simon
He, Anna
Langer-Gould, Annette
Hillert, Jan
Frisell, Thomas
author_facet McKay, Kyla A.
Piehl, Fredrik
Englund, Simon
He, Anna
Langer-Gould, Annette
Hillert, Jan
Frisell, Thomas
author_sort McKay, Kyla A.
collection PubMed
description This case-control study examines the risk of severe COVID-19 infection in individuals with multiple sclerosis who were receiving rituximab.
format Online
Article
Text
id pubmed-8637249
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-86372492021-12-08 Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden McKay, Kyla A. Piehl, Fredrik Englund, Simon He, Anna Langer-Gould, Annette Hillert, Jan Frisell, Thomas JAMA Netw Open Research Letter This case-control study examines the risk of severe COVID-19 infection in individuals with multiple sclerosis who were receiving rituximab. American Medical Association 2021-12-01 /pmc/articles/PMC8637249/ /pubmed/34851401 http://dx.doi.org/10.1001/jamanetworkopen.2021.36697 Text en Copyright 2021 McKay KA et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Research Letter
McKay, Kyla A.
Piehl, Fredrik
Englund, Simon
He, Anna
Langer-Gould, Annette
Hillert, Jan
Frisell, Thomas
Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
title Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
title_full Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
title_fullStr Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
title_full_unstemmed Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
title_short Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
title_sort rituximab infusion timing, cumulative dose, and hospitalization for covid-19 in persons with multiple sclerosis in sweden
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637249/
https://www.ncbi.nlm.nih.gov/pubmed/34851401
http://dx.doi.org/10.1001/jamanetworkopen.2021.36697
work_keys_str_mv AT mckaykylaa rituximabinfusiontimingcumulativedoseandhospitalizationforcovid19inpersonswithmultiplesclerosisinsweden
AT piehlfredrik rituximabinfusiontimingcumulativedoseandhospitalizationforcovid19inpersonswithmultiplesclerosisinsweden
AT englundsimon rituximabinfusiontimingcumulativedoseandhospitalizationforcovid19inpersonswithmultiplesclerosisinsweden
AT heanna rituximabinfusiontimingcumulativedoseandhospitalizationforcovid19inpersonswithmultiplesclerosisinsweden
AT langergouldannette rituximabinfusiontimingcumulativedoseandhospitalizationforcovid19inpersonswithmultiplesclerosisinsweden
AT hillertjan rituximabinfusiontimingcumulativedoseandhospitalizationforcovid19inpersonswithmultiplesclerosisinsweden
AT frisellthomas rituximabinfusiontimingcumulativedoseandhospitalizationforcovid19inpersonswithmultiplesclerosisinsweden

Ejemplares similares